The Democratic Republic of Congo has commenced vaccinations against Ebola, aiming to control the world's most rapidly expanding outbreak of the disease. Health workers and other frontline responders are being prioritized to receive the Ervebo vaccine, which has proven effective in previous outbreaks caused by different Ebola strains. This campaign is being conducted under a compassionate-use program, allowing the vaccine's use for the current outbreak strain, known as the Bundibugyo virus, while clinical trials are underway to determine its specific efficacy against it.
As of Friday, Congo had recorded 5,794 confirmed cases and 2,786 deaths. The outbreak has spread to two new health zones, Biena and Manguredjipa in North Kivu province, bringing the total affected to 60. The case fatality rate in these new zones is higher than the overall rate, partly due to delayed response efforts. The World Health Organization has described the situation as out of control, exacerbated by insecurity, displacement, a health workers' strike, and significant population movements.
More than 70,000 doses of the Ervebo vaccine have been approved for use, with approximately 50,000 doses allocated for frontline personnel and 20,000 for a clinical trial studying its effectiveness against the Bundibugyo virus. Data collected during the vaccination drive will be used to assess the vaccine's performance. The campaign is set to cover health zones across Tshopo, Bas-Uele, and Haut-Uele provinces, with health authorities strongly encouraging vaccination to protect workers and prevent further community transmission.